Patient selection strategies throughout the renal cell carcinoma disease spectrum KU Leuven
We propose to determine molecular subtypes of primary and metastatic clear-cell renal cell carcinomas (ccRCC) and their detailed immune phenotypes. Although immune checkpoint inhibitors (ICI) have become the backbone for metastatic ccRCC treatment, the reasons for their particular efficacy in ccRCC are poorly understood and current combination strategies to boost ICI efficacy fail to adapt to important intertumoral heterogeneity. We recently ...